No Advantage for Rhythm Control in Post-Cardiac Surgery AF

This meta-analysis clarifies that rhythm control offers no length-of-stay, thromboembolic, or mortality benefit over rate control for postoperative atrial fibrillation, while aggressive antiarrhythmics raise hemodynamic harm.

amiodaroneibutilideprocainamidepropafenonesotalolflecainidemetoprololdiltiazemdigoxinverapamilrate controlrhythm controlpostoperative atrial fibrillationcardiac surgeryanticoagulationmeta-analysissystematic review Cardiology / Anticoagulation

Background Information

Rhythm control offers no clear advantage over rate control post-cardiac surgery.

Postcardiac surgery atrial fibrillation can affect recovery and outcomes, necessitating effective treatment strategies. No significant difference in hospital stay was found; rhythm control improved sinus rhythm but increased adverse events versus rate control. Rhythm control strategies may offer conversion benefits but come with higher risks, suggesting limited advantage over rate control in this setting. Rhythm control does not outperform rate control in improving outcomes post cardiac surgery.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Dairi MS, Tarabzoni M, Tarola C, Sehmbi H, Alwafi H, Alghamdi SM, Khan S, Alotaibi WT, Hegazy AF

Citation: Dairi MS, Tarabzoni M, Tarola C, et al. Rhythm vs. rate control for treatment of postoperative atrial fibrillation after cardiac surgery: a systematic review and meta-analysis of randomized controlled trials. Frontiers in cardiovascular medicine. 2026;13:1820175. doi:10.3389/fcvm.2026.1820175

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →